Benitec Biopharma

Benitec Biopharma

BNTC· Manufacturing· Fiscal year ends in June

CEO pay in FY2025Stock +67.4% in FY2025

Dr. Jerel Banks, M.D. Ph.D is the CEO of Benitec Biopharma and was paid $25.9M in FY2025 (Jun), up 719%.

Pay$100 in the stock at the end of FY21 → $16
CEO pay is from each Benitec Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Dr. Jerel Banks, M.D. Ph.DFY2025
  2. 2Megan BostonFY2025
  3. 3Sophie MukadamFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Benitec Biopharma paid its 3 named executives $38.2M in total in FY2025 (Jun). CEO Dr. Jerel Banks, M.D. Ph.D was paid $25.9M of that.

Name
Dr. Jerel Banks, M.D. Ph.DChairman and Chief Executive Officer
Megan BostonChief Financial Officer, Secretary
Sophie MukadamChief Operating OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Benitec Biopharma. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board2

See all
  • Megan BostonDirector · 9 yr on the boardNot independent—Paid as an executive
  • Edward SmithDirector · 5 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AOct 14, 2025FY2025
Annual report10-KSep 22, 2025FY2025
Annual report10-KSep 26, 2024FY2024
Proxy statementDEF 14AJul 29, 2024—
Proxy statementDEF 14AOct 20, 2023FY2023
Annual report10-KSep 21, 2023FY2023
For the press:Download CSVDownload PNGHow to use our data